π-HuB: the proteomic navigator of the human body
- PMID: 39663494
- DOI: 10.1038/s41586-024-08280-5
π-HuB: the proteomic navigator of the human body
Erratum in
-
Author Correction: π-HuB: the proteomic navigator of the human body.Nature. 2025 Jan;637(8046):E22. doi: 10.1038/s41586-024-08555-x. Nature. 2025. PMID: 39715925 No abstract available.
Abstract
The human body contains trillions of cells, classified into specific cell types, with diverse morphologies and functions. In addition, cells of the same type can assume different states within an individual's body during their lifetime. Understanding the complexities of the proteome in the context of a human organism and its many potential states is a necessary requirement to understanding human biology, but these complexities can neither be predicted from the genome, nor have they been systematically measurable with available technologies. Recent advances in proteomic technology and computational sciences now provide opportunities to investigate the intricate biology of the human body at unprecedented resolution and scale. Here we introduce a big-science endeavour called π-HuB (proteomic navigator of the human body). The aim of the π-HuB project is to (1) generate and harness multimodality proteomic datasets to enhance our understanding of human biology; (2) facilitate disease risk assessment and diagnosis; (3) uncover new drug targets; (4) optimize appropriate therapeutic strategies; and (5) enable intelligent healthcare, thereby ushering in a new era of proteomics-driven phronesis medicine. This ambitious mission will be implemented by an international collaborative force of multidisciplinary research teams worldwide across academic, industrial and government sectors.
© 2024. Springer Nature Limited.
Conflict of interest statement
Competing interests: R.A. holds shares of Biognosys AG, which operates in the field covered by the article. D.F. is co-founder of MedBiome Inc., a precision nutrition company. K.G. is a shareholder of CYBO, LucasLand, and FlyWorks. T.G. is the founder of Westlake Omics Inc. M.M. is an indirect investor in EvoSep. R.T. is a founder of BayOmics. The other authors declare no competing interests.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
